Kazam Joshua A

Kazam Joshua A is listed in filings as Director at Allogene Therapeutics, Inc.. This profile follows SEC Form 4 activity through Dec 22, 2025, including 8 public disclosures. Recent filings connect the profile to Allogene Therapeutics, Inc. (ALLO) and Kronos Bio, Inc. (KRON). The current snapshot covers public activity from Jun 26, 2024 to Dec 22, 2025. Reported amounts are shown as $498.1K to $53.9K. The page organizes purchases, sales, issuer links, reported share activity, and filing evidence for review as public disclosure data.